Multi-antigen T cell therapy for relapsed NHL
Official title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
Funded at Marker Therapeutics, INC. · NIH-11374461 · Data updated 2026-11-12
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Marker Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $665,000 |
| NIH project number | 5R44CA291521-03 |
| Project ID | NIH-11374461 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed non-Hodgkin lymphoma who have previously received CAR T cell therapy and meet safety criteria for cellular therapies.
✕Less likely to help
Some patients may not respond or may experience treatment-related toxicities without clinical benefit.
What this research studies
MT-601 uses a patient’s own blood cells, which are engineered to recognize six cancer-related proteins and then infused back to fight the lymphoma. The approach relies on natural T cell receptors to attack tumor cells presenting any of the six targeted antigens, potentially engaging both helper and killer immune responses. The study focuses on safety and initial signs of activity in people whose NHL has returned after CAR T cell therapy, aiming to offer a new option where current treatments may no longer work. Participants will undergo apheresis to collect cells, followed by manufacturing and infusion of MT-601 with careful monitoring for side effects. This early-phase work seeks to establish feasibility and pave the way for broader testing if results are favorable.
Why it matters
Potential benefit: If successful, MT-601 could provide a new treatment option for relapsed NHL by targeting multiple cancer markers to improve tumor killing and reduce relapse.
How similar studies have gone: Early cellular therapies targeting multiple antigens have shown promise in NHL, but this multi-antigen approach is novel and exploratory.
Where this research is happening
-
Marker Therapeutics, INC.
Houston, United States Active
Researchers
- Principal investigator: Vera, Juan Fernando — Marker Therapeutics, INC.
- Study coordinator: Vera, Juan Fernando
Related research
Other NIH-funded projects on the same topics.
-
MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma
This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.
-
New T cell therapy for patients with relapsed Non-Hodgkin Lymphoma
This study is testing a new treatment for people with relapsed Non-Hodgkin Lymphoma that uses their own immune cells to better fight cancer by targeting multiple markers on the cancer cells, with the hope of making the treatment more effective and lowering the risk of the cancer coming back.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Precision targeted radioactive antibody therapy for non-Hodgkin lymphoma
Researchers are developing more precise radioactive antibodies to treat people with CD20-positive non-Hodgkin lymphoma.
-
AI-designed drugs targeting a common lymphoma mutation (MYD88 L265P)
Researchers are using artificial intelligence to create and test new drugs that block a common MYD88 mutation found in many B‑cell non‑Hodgkin lymphomas to help people with these cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.